Morbidity and Mortality Weekly Report: Recommendations and Reports, August 23, 2019 / Vol. 68 / No. RR-3

Details

• Alternative Title:
  Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Grohskopf, Lisa A. ; Alyanak, Elif ; Broder, Karen R. ; Walter, Emmanuel B. ; Fry, Alicia M. ; Jernigan, Daniel B.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
• Description:
  This report updates the 2018–19 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2018;67[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2019–20 season. Standard-dose, unadjuvanted, inactivated influenza vaccines will be available in quadrivalent formulations (IIV4s). High-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines will be available in trivalent formulations. Recombinant (RIV4) and live attenuated influenza vaccine (LAIV4) will be available in quadrivalent formulations.
  
  Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 25, 2018; February 27, 2019; and June 27, 2019. Primary updates in this report include the following two items. First, 2019–20 U.S. trivalent influenza vaccines will contain hemagglutinin (HA) derived from an A/Brisbane/02/2018 (H1N1)pdm09–like virus, an A/Kansas/14/2017 (H3N2)–like virus, and a B/Colorado/06/2017–like virus (Victoria lineage). Quadrivalent influenza vaccines will contain HA derived from these three viruses, and a B/Phuket/3073/2013–like virus (Yamagata lineage). Second, recent labeling changes for two IIV4s, Afluria Quadrivalent and Fluzone Quadrivalent, are discussed. The age indication for Afluria Quadrivalent has been expanded from ≥5 years to ≥6 months. The dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for all persons aged ≥36 months (≥3 years). The dose volume for Fluzone Quadrivalent for children aged 6 through 35 months, which was previously 0.25 mL, is now either 0.25 mL or 0.5 mL. The dose volume for Fluzone Quadrivalent is 0.5 mL for all persons aged ≥36 months (≥3 years).
  
  This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2019–20 season in the United States. A brief summary of these recommendations and a Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration–licensed indications. Updates and other information are available from CDC’s influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.
  
  Suggested citation for this article: Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season. MMWR Recomm Rep 2019;68(No. RR-3):1–21. DOI: http://dx.doi.org/10.15585/mmwr.rr6803a1
  
  
• Subjects:
  Adolescent Adult Aged Child Child, Preschool Female Humans Immunization Schedule Infant Influenza, Human / Epidemiology Influenza, Human / Prevention & Control Influenza Vaccines / Adverse Effects Influenza Vaccines / Therapeutic Use Male Middle Aged Pregnancy Risk Assessment Seasons

  More +
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2019; v. 68, no. 3
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.rr6803a1
• ISSN:
  1057-5987 (print) ; 1545-8601 (digital)
• Document Type:
  Journal Issue
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  28 pdf pages
• Volume:
  68
• Issue:
  3
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:a0949d57ca4cfcf09b10941e270560ba8312d13e9eae9c7b845600ecb6a65135924f3689ef27c97e9d0e7e3c81f8ad165eaffc0316435b6627e7319db7a35e7e
• Download URL:
  https://stacks.cdc.gov/view/cdc/80811/cdc_80811_DS1.pdf
• File Type:
  [PDF - 772.61 KB ]